Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

g. OGX-427 is designed to reduce levels of Hsp27, a heat shock protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy, and radiation therapy. Results demonstrated that OGX-427 was safe and well tolerated as monotherapy, as well as in combination with docetaxel. In addition, when OGX-427 was used as a single agent there were declines in circulating tumor cells in patients at all doses and in all diseases evaluated, as well as evidence of reduction in tumor markers in prostate and ovarian cancer. - Partnering discussions and assessment of other opportunities to expand the development plan into additional randomized Phase 2 trials will continue. - A Phase 1 trial in bladder cancer is currently underway. - A randomized Phase 2 trial in CRPC is expected to initiate later this year.

Financial Results

Under our Collaboration Agreement with Teva relating to our contribution to the custirsen Phase 3 development plan, we earned Collaboration Revenues of $1.7 million and $6.4 million, respectively, for the three and six months ended June 30, 2010, compared to no revenues in the corresponding periods of 2009. Of the revenues in the second quarter, $362 thousand is reimbursable from Teva on a cash basis and is included on the Company's balance sheet as amounts receivable at June 30, 2010. As of June 30, 2010, $24.1 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our del
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 Strategic marketing and branding agency, ... name, Able&Co. , The agency was founded in 2008 ... its inception, continuing to expand its business each year. ... with a core focus on branding and marketing strategy. ... name and visual identity to reflect who we have ...
(Date:3/6/2015)... Global Specimen Solutions, Inc. ( http://www.globalspecimensolutions.com ... management and informatics, announced today that Series A ... is excited to catapult our growing momentum in ... enhance our proprietary informatics tools and infrastructure to ... has proved rapid market uptake of our clinical ...
(Date:3/6/2015)... , March 6, 2015   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... Company,s fourth quarter and full year 2014 financial results will ... the Company will host a conference call and live ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... veterans to be able to get an Advanced Semen ... money, stress, blaming and guessing are all risk factors ... assuming the woman is the source of the infertility. ... female. LifeCell Dx has the simplest, least complicated ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... recently participated in a roundtable discussion with HR executives ... talent management and resourcing strategies for elite multinational firms. ... how to make the work place and the workforce ... to make sure that companies always have the right ...
... its release of GroupWise Migrator for Exchange Version 2.2, ... of server and desktop data from Novell GroupWise to ... for Exchange could convert mail, archives, personal address books, ... Exchange. The new version adds the ability to migrate ...
... The time has come to reexamine the federal policy on ... itself at the center of this debate, because our state ... In 1998, Dr. Jamie Thomson at the University ... the first time, successfully isolated stem cells from human embryos ...
Cached Biology Technology:Stuck in Talent Gridlock 2Stuck in Talent Gridlock 3Wingra Technologies releases new e-mail-message migration software 2Gov. Doyle comments on unlocking the power of power of stem cell research 2Gov. Doyle comments on unlocking the power of power of stem cell research 3
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... French colonial-style exterior of the National Cancer Hospital in Hanoi, ... hospitals crowded wards, treatment rooms and corridors, doctors are struggling ... the disease is winning. Each year in this country ... cancer and another 150,000 new cases are diagnosed. Figures are ...
... United States die every year from uncontrolled infections of ... pushing the boundaries of molecular science to find new ... measure of an immune system protein within 24 hours ... can predict survival in children, yielding a powerful tool ...
... in Germany have discovered that methadone, an agent used ... power against leukemia cells, including treatment resistant forms of ... August 1 issue of Cancer Research , a ... that methadone holds promise as a new therapy for ...
Cached Biology News:In Vietnam, alongside progress, a battle for life 2In Vietnam, alongside progress, a battle for life 3Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3Lab study shows methadone breaks resistance in untreatable forms of leukemia 2
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
...
Request Info...
...
Biology Products: